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Abstract
Background—Globally, 49% of the estimated 1.8 million children living with HIV are accessing 
antiretroviral therapy (ART). There are limited data concerning long-term durability of first-line 
ART regimens and time to transition to second-line.
Methods—Children initiating their first ART regimen between 2–14 years of age and enrolled in 
one of 208 sites in 30 Asia-Pacific and African countries participating in the Pediatric 
International Epidemiology Databases to Evaluate AIDS consortium were included in this 
analysis. Outcomes of interest were: First-line ART failure (clinical, immunologic, or virologic), 
change to second-line, and attrition (death or loss to program [LTP]). Cumulative incidence was 
computed for first-line failure and second-line initiation, with attrition as a competing event.
Results—In 27,031 children, median age at ART initiation was 6.7 years. Median baseline 
CD4% for children ≤5 years was 13.2% and CD4 count for those >5 years was 258 cells/µl. 
Almost all (94.4%) initiated a non-nucleoside reverse transcriptase inhibitor (NNRTI); 5.3% a 
protease inhibitor (PI), and 0.3% a triple nucleoside (NRTI)–based regimen. At one year, 7.7% had 
failed and 14.4% had experienced attrition; by five years, the cumulative incidence was 25.9% and 
29.4%, respectively. At one year after ART failure, 13.7% had transitioned to second-line and 
11.2% had experience attrition; by five years, the cumulative incidence was 31.6% and 25.9%, 
respectively.
Conclusions—High rates of first-line failure and attrition were identified in children within five 
years after ART initiation. Of children meeting failure criteria, only one-third were transitioned to 
second-line ART within five years.
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Background
As of 2015, globally 1.8 million children were living with HIV, the vast majority of whom 
resided in low- and middle-income countries (LMIC).1 Of these children (ages 0–14), 49% 
were accessing treatment, ranging from 20% in West and Central Africa to >95% in Europe 
and North America.1,2 The effectiveness of combination antiretroviral therapy (ART) in 
children is undisputed, with 12-month viral suppression rates ranging from 49–83.3%.3–10 
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However, there are limited data from LMIC concerning the long-term durability of first-line 
ART regimens. Because children in LMIC HIV treatment programs tend to start treatment at 
older ages with significant immune compromise, and are often monitored in the absence of 
virologic data, estimates of first-line ART durability taken from high-income settings may 
not be generalizable to these programs.11, 9,12 Though targeted viral load (VL) testing is 
currently recommended to confirm suspected failure many public-sector programs still rely 
on clinical and immunologic criteria to detect therapeutic failure, and are likely to continue 
to do so in full or in part because of issues with access to equipment, reagents or availability 
of consistent specimen transport to reference laboratories.13 Within this context it is 
important to understand the cumulative incidence of failure and the time to transition to 
second-line ART.
The cumulative incidence of switch to second-line ART in children has been assessed in 
both clinical trials and cohort studies. However, studies vary with regard to the initial ART 
regimen, monitoring strategy and definitions for the switch to a second regimen. The 
proportion switched to second-line after five years on treatment in the EPPICC Cohort and 
the PENPACT Trial were 35% and 29%, respectively.4,6 In Asia, the proportions of switch to 
second-line have been reported at 22% and 17.6% in cohorts with median on ART 
observation periods of 4.5 years and 4.9 years, respectively.14,15 However, much lower rates 
of switch have been reported from sub-Saharan Africa, with one observational cohort from 
South Africa reporting a three-year estimated probability of switch of only 6.2%, and the 
ARROW trial reporting switch rates at approximately 2 years on ART of 5%–6%.10,16 With 
the exception of the ARROW Trial, which identified failure based on clinical or 
immunologic criteria, the above studies predominately or exclusively utilized VL criteria for 
failure. As the positive predictive value of the WHO’s immunologic criteria for failure has 
been estimated to range from 20.0 to 54.9% in children, there is a high likelihood that first-
line failure is significantly under-diagnosed in studies and programs utilizing CD4 
monitoring in the absence of VL.17 Of note, while the South African cohort only had a 6.2% 
cumulative incidence of switch, the cumulative incidence of virologic failure was 19.3%, 
thus suggesting that even in the face of virologic failure there may be issues with 
transitioning antiretroviral regimens.16
In light of the complex environment in which HIV-infected children in LMIC are being 
assessed for failure and transitioned to second-line regimens, the International Epidemiology 
Databases to Evaluate AIDS (IeDEA) consortium sought to explore the time to and factors 
associated with ART failure as well as change to second-line in children initiating ART 
between 2–14 years of age.
Methods
Study Design and Setting
This retrospective cohort study utilized de-identified patient-level and site-level data drawn 
from the IeDEA Pediatric Cohort. The IeDEA consortium is composed of seven regional 
data centers that collect, harmonize, and analyze data drawn from HIV care and treatment 
programs within their region. Data from five of the IeDEA Pediatric Cohorts (Asia-Pacific; 
East Africa; West Africa; Central Africa; Southern Africa) are represented in this analysis.18 
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The Central African clinics are represented twice as Central Africa 1.0 and Central Africa 
2.0 because the clinics within the region differ between two time periods.
This analysis was approved, as part of East Africa IeDEA, by the Indiana University 
Institutional Review Board (IRB) as well as local, and where required national, regulatory 
bodies affiliated with the participating programs and regional data centers. The majority of 
participating sites and regulatory bodies do not require written informed consent for the use 
of de-identified routinely collected patient-level data.
Study Population
ART-naïve HIV-infected children enrolling in care prior to 10 years of age and initiating 
their first ART regimen with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based, triple nucleoside reverse transcriptase inhibitor (NRTI)-based, or protease inhibitor 
(PI)-based three to four drug regimens between the ages of 2 and 14 years were included in 
this analysis. Children under 2 years were ineligible because the WHO clinical and 
immunologic criteria for failure were not well defined for this age group when the study was 
designed. Many HIV programs transition children from the pediatric to the adult clinic at 14 
years and so 14 years was chosen as the upper age limit for inclusion. Children were 
excluded if they did not initiate a standard and consistent ART regimen, VL data were 
inconsistent (two VL tests on the same day with different values), there were no visits after 
ART initiation, or if their age was inconsistently documented (Figure 1).
Data Collection and Management
Data were collected as part of routine clinical care via locally designed data collection 
instruments and then transcribed into the local electronic patient database. Laboratory 
studies, such as HIV VL and CD4 cell counts, were analyzed by local clinical laboratories 
utilizing local protocols and procedural standards. Vital status ascertainment was variable 
across sites with some sites having active tracing programs for those LTP and other sites 
relying on passive death reporting.
De-identified data were transferred from local programs to affiliated regional data centers 
harmonization and transfer to the East African Regional Data Center (EA-RDC) where a 
single analysis dataset was created. Data quality checks were incorporated into each step of 
the process. This analysis utilized patient-level data collected from 02/1994 to 02/2015 
depending on region-specific data availability. Additional data were collected through two 
site-level surveys, which assessed programmatic factors such as recommended first and 
second-line ART regimens, antiretroviral availability, monitoring strategies (clinical, 
immunologic and/or virologic monitoring) and criteria for failure over the life of the 
program, as well as site characteristics such as facility type (public, academic, non-profit/
private), location (urban, rural, in-between), population served (family [adults and children] 
or children only). The site-level data were assessed up to 2011–2012 for the majority of 
programs.
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Analysis
The primary outcome of interest was the time to first-line ART failure. A minimum of 24 
weeks on ART were required prior to being eligible for an assessment of failure. Clinical 
failure was defined as the appearance or reappearance of a WHO stage 3 or 4 condition. 
Immunologic failure was defined as the development or return to age-associated CD4 cell 
thresholds including an absolute CD4 count of less than 200 cells/µl or a CD4 percent of less 
than 10% for children between 2 and 5 years, as well as a CD4 count less than 100 cells/µl 
for children 5 years or older. Virologic failure was defined as a single VL measurement 
exceeding 5000 copies/ml, consistent with the WHO Guidelines when this analysis was 
designed.13
Throughout this analysis the decision hierarchy for failure assumed that virologic parameters 
superseded immunologic parameters which in turn superseded clinical parameters. The first 
VL measurement within 6 months after an immunologic or clinical failure event was used to 
determine the failure status. Likewise, if the first CD4 count within 2 months after a clinical 
failure did not meet immunologic criteria for failure, then the clinical failure was superseded 
by immunologic status. If a clinical failure event was documented and no immunologic or 
VL data were available then the patient was considered to have failed. An example of the 
decision analysis: If a patient had a WHO stage-4 event, a CD4 cell count less than 100 
cells/µl but had an undetectable VL within 6 months after the clinical and immunologic 
failure events, in the absence of a change in ART regimen, they were not considered to have 
failed their ART regimen.
The secondary outcome of interest was the time from first-line ART failure to change to 
second-line ART, defined as a class change in the base component (e.g., NNRTI to PI or vice 
versa) and a change in at least one NRTI. Attrition (death or LTP) was used as a competing 
risk in both the time to first-line ART failure and time to change to second-line analyses. 
Death and LTP were viewed as the composite variable attrition in both analyses, because 
death is frequently under reported within sub-Saharan African ART programs and 
consequently may be misclassified as LTP.19 LTP was defined as no visit during the 6 
months prior to database closure in the absence of documented death, transfer, or relocation 
outside of the clinic catchment.
Covariates assessed at ART initiation included sex, WHO stage, age, CD4 and weight-for-
age Z-score (WAZ), facility location, facility type, population served, whether the site began 
providing ART before or after 2004, site virologic monitoring (confirmatory VL, routine 
VL, or no VL), and composition of the first-line regimen (NNRTI versus PI-based). WHO 
stage was converted into a binary variable WHO-stage1–2 versus 3–4. WAZ was defined 
using the 2000 CDC Growth Charts for ages 0 to <20 years.20 Sites that monitored VL every 
6 –12 months were defined as routine VL sites while sites that used VL to confirm clinical 
or immunologic failure were defined as confirmatory VL sites. Neither the IeDEA region 
nor the country were included as factors in the proportional hazards model due to co-
linearity with other variables (e.g., type of monitoring strategy).
Missing CD4 counts were imputed using a mixed-effects model with a spline in the time 
factor, where the outcome was the longitudinal CD4 count and the predictors included a 
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random intercept, baseline age, sex, and the spline basis functions. The subject-specific 
effect was estimated from the above model, and it was used to estimate the corresponding 
subject’s missing CD4 cell count adjusting for age at ART initiation and sex. Missing WAZ 
and WHO stage at ART initiation were similarly imputed using a linear regression model, 
where the outcome was the WAZ at ART initiation or the WHO stage, and the predictors 
included sex, age and CD4 cell count at ART initiation. Children missing, at baseline, both 
CD4 count and WHO stage or missing both CD4 count and WAZ, as well as those with no 
CD4 data at any time during follow-up were excluded from the multivariable analysis but 
included in the univariate analysis. It should be noted that imputed quantities were used only 
in the multivariable models as risk factors of failure and switch to second line ART after 
failure but were not used to define treatment failure (clinical or immunologic).
Medians and interquartile ranges (IQR) for continuous variables and frequency percentages 
for categorical factors were calculated based on the observed data. Cumulative incidence 
was computed for first-line failure and second-line regimen initiation. Attrition was treated 
as a competing event as described earlier.
Patients not experiencing the outcome of interest or a competing event were censored on the 
database closure date. A cause-specific proportional hazards model was used to identify 
factors associated with each outcome. Hazard ratios were calculated for each covariate in the 
cause-specific proportional hazards model. Because of available data spanned more than two 
decades in some cases, there was the concern that some of the results of these analyses 
might not be generalizable to more recent calendar periods. To address this potential 
concern, we performed a sensitivity analysis where data were restricted to persons initiating 
ART during the most recent five years of available data (ART initiation no earlier than 
December 31, 2010). All analyses were implemented in R, Version 3.0.2. P-values less than 
0.05 were considered significant.
Results
Data were contributed by 208 clinical sites from 30 countries. Of the 31,871 records 
received by the EA-RDC, 4,840 were not included in the analysis for one or more of the 
following reasons: ART-initiated prior to enrollment; never initiated ART; ART regimen was 
incomplete or inconsistent; age data were inconsistent; or there were insufficient visit data 
(Figure 1). Of the remaining 27,031 children, 52.8% were from Southern Africa, 27.8% East 
Africa, 7.2% Asia-Pacific, 6.4% West Africa, and 5.9% from Central Africa (Table 1). 
Children came predominately from clinics that were pediatric-specific (69.1%), publicly 
operated (59.4%), were located in between an urban and rural area (49.3%), and began 
operation prior to 2004 (62.9%).
The proportion of clinics reporting use of routine VL monitoring increased from 7% for 
2004 to 21.2% for 2011–2012. For 2004, 99.4% of clinics reported the use of an NNRTI, 
6.6% a PI, and 3.0% a NRTI-based first-line regimen. For 2011–2012, 100% of clinics 
reported the use of an NNRTI, 47.5% a PI, and 1.0 % a NRTI-based first-line regimen. For 
2004, 95.8% of clinics reported that they had access to second-line ART regimens while 
99.0% reported that they had access for 2011–2012.
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Among the 27,031 children included in this analysis, there were nearly equal proportions of 
male and female children. The median age at first visit was 6.1 years (IQR: 3.5–9.1) while 
the median age at ART initiation was 6.7 years (IQR: 4.2–9.7) (Table 1). At ART initiation, 
the median CD4 percent for children <5 years was 13.2% (IQR 8.7–19.0) and the median 
CD4 count for children ≥5 years was 258 cells/µl (IQR: 112–444). The vast majority 
(94.4%) of children initiated an NNRTI-, 5.3% a PI- and 0.3% a NRTI-based regimen.
During 19.5 months of median follow-up after ART initiation, 4,763 children were identified 
as having failed first-line ART with the mode of ascertainment for the earliest failure event 
being 32.4% by clinical, 22.2% by immunologic, and 45.4% by virologic criteria. During the 
same period 6,037 children experienced an attrition event. The cumulative incidence of any 
type of failure at one and five years after ART initiation was 7.7% (95% CI: 7.4–8.1) and 
25.9% (95% CI: 25.6–27.0), respectively (Figure 2a). At one and five years after ART 
initiation, the cumulative incidence of attrition was 14.4% (95% CI: 14.1–15.-0) and 29.4% 
(95% CI: 29.1–30.5), respectively (Figure 2a).
In an analysis involving the 22,257 children with available data, factors at ART initiation 
associated with failure or attrition, in the univariate analyses, are outlined in Table 2. In a 
multivariable analysis, the factors at ART-initiation that were associated with a lower hazard 
of any type of failure were higher WAZ, higher CD4 count, enrollment at a private clinic or 
a clinic starting ART provision after 2004, while a higher hazard of failure was associated 
with being male, having a higher WHO stage, initiating a PI-based regimen, or enrollment at 
an in-between clinic. A lower hazard of attrition was significantly associated with older age, 
higher WAZ, higher CD4 cell count, enrollment at a rural clinic, a family clinic, a clinic 
starting ART provision after 2004, or a clinic using any VL testing. Higher WHO stage and 
being enrolled at a private clinic were significantly associated with a higher hazard of 
attrition. In the analyses based on data from the most recent five years (sensitivity analyses 
described in the Methods, not shown), the results were virtually identical with those of the 
overall multivariable analyses presented above.
The 4,763 patients identified with first-line ART failure were followed for a median of 14.3 
months after a failure event during which 990 (20.8%) were transitioned to second-line and 
833 (17.5%) had an attrition event. The cumulative incidence of switch to second-line ART 
for the entire cohort (irrespective of failure) at one and five years after ART initiation was 
0.38% (95% CI: 0 – 1%) and 0.49% (95% CI: 0 – 1%), respectively. Among those with a 
documented failure event, the cumulative incidence of change to second-line at one and five 
years after failure was 13.7% (95% CI: 12.9–15.0) and 31.6% (95% CI: 30.9–32.4), 
respectively (Figure 2b). The cumulative incidence of attrition at one and five years after 
failure was 11.2% (95% CI: 10.5–12.4) and 25.9% (95% CI: 25.1–28.8), respectively 
(Figure 2b).
Among 4,120 children with available data, factors at ART initiation associated with change 
to second-line ART or attrition, in the univariate analyses, are outlined in Table 3. In a 
multivariable analysis, baseline factors that were associated with a lower hazard of change to 
second-line ART after failure included a higher CD4 cell count, PI-based first-line, and 
enrollment in a family clinic, an in-between clinic, or an academically affiliated clinic. 
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Being male, older, and enrolled in a clinic with confirmatory VL testing was associated with 
a higher hazard of switch to second-line ART. Baseline factors that were associated with a 
lower hazard of attrition after first-line ART failure included higher WAZ, higher CD4 cell 
count, enrollment in a family clinic, or an academically affiliated clinic. Receiving care at a 
private clinic was significantly associated with a higher hazard of attrition after failure 
(Table 3). In the analyses based on data from the most recent five years (not shown), the 
results were virtually identical with those of the overall multivariable analyses presented 
above.
Discussion
This five-region analysis of data from sub-Saharan Africa and Asia demonstrated a high rate 
of first-line failure (25.9%) among children at five years after ART initiation. Data for 
comparison are limited, as most studies utilize the rate of switch to second-line or VL failure 
as the outcome measures when assessing first-line ART durability while our study utilizes a 
site-dependent composite failure variable that includes clinical, immunologic, and/or VL 
criteria. Though not directly comparable, our failure rates appear somewhat lower than the 
PENPACT trial, which reported a failure rate of 36% (VL ≥1,000 copies/mL) at a median of 
five years after ART initiation.21 Our results appear consistent with the ARROW Trial, 
which reported virologic failure (>400 copies/mL) in approximately 23% of children at a 
median of 3.7 years and somewhat higher than data from Soweto reporting virologic failure 
(confirmed VL >1000) in 16.3% of children at a median of 36 months.22
In the multivariable analysis, failure was associated with a PI-based regimen but not with 
routine VL testing. This finding is counter to our a priori assumptions. An additional 
exploratory analysis showed that the proportion of patients on a PI-based regimen with a VL 
was significantly greater than for individuals on an NNRTI-based regimen (p <0.001). Based 
on this finding, we posit that there is confounding by site, as the sites most likely to have 
routine VL testing, primarily in South Africa, are also have a higher proportion of children 
on PI-based first-line ART. Other factors that may have contributed to the finding of an 
association between PI-based first line regimen and failure include the possibility of co-
linearity with age (in South Africa PI-based ART is initiated in children <3 years) and the 
use of unboosted PIs in the early phase of ART rollout in some countries. Additional factors 
associated with an increased hazard of failure were, not unexpectedly, related to the child’s 
disease severity at ART initiation, including higher WHO stage, lower WAZ and lower CD4 
count. Results from the sensitivity analyses focusing on patients initiating ART during the 
most recent five years were identical to those involving the complete database. This suggests 
that the associations between various predictors and the cause-specific hazards of attrition or 
of treatment failure were generally consistent throughout the observation period and, more 
importantly, are still relevant in the current reality of HIV pediatric patient care.
At one year after first-line failure, the cumulative incidence of reaching one of the study 
endpoints of change to second-line ART (13.7%) or attrition (11.2%) was 24.9%. Thus 
75.1% of children, one year after meeting criteria for first-line failure, were still in care and 
on a first-line regimen. The one-year rate of switch to second-line therapy in our analysis is 
significantly lower than that previously reported by the Southern Africa IeDEA region (38% 
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within one-year of virologic failure).16 Though the data in this analysis are insufficient to 
explore factors contributing to a physician’s assessment of failure, our findings that a lower 
CD4 count was associated with an increased probability of switch and that a PI-based 
regimen was associated with a lower probability of switch, similar to the South African 
analysis, suggest that multiple factors impact a clinician’s decision to transition a patient to 
second-line ART.16 Delays in switch to second-line may be related to clinician concerns 
about the diagnostic accuracy of the failure criteria; the availability or effectiveness of 
subsequent ART regimens; as well as implementation of interventions to improve adherence.
The use of routine VL monitoring was not associated with a higher likelihood of switch after 
failure, but was associated with a trend toward a lower likelihood of attrition after failure. 
This finding persisted in the sensitivity analysis focusing on patients initiating ART during 
the most recent five years of data, thus the increasing use of routine VL in the most recent 
period did not modify the association between various predictors and the likelihood (hazard) 
of initiating second-line ART regimens. Since the endpoint for this analysis was the first 
failure event, in neither the initial analysis nor in the sensitivity analysis did we assess 
whether or not patients subsequently suppressed their VL without a regimen change. It is 
possible that a detectable VL triggered an adherence intervention that subsequently led to 
suppression, which obviated the need for a regimen change. In addition, academic and 
family-based clinics were less likely to transition patients to second-line, but also had lower 
hazards of attrition after failure compared to public or child-only clinics. This leads us to 
speculate that these clinics may implement adherence intervention strategies, triggered by 
identification of a failure event, prior to enacting a transition to second-line ART.
Because the data used in this analysis came from HIV clinical programs, there are a number 
of weaknesses in the study. Death was passively reported by most programs. Consequently, 
there is the potential for individuals who have died to be misclassified as being LTP.23 In 
addition, individuals who are LTP may be engaged in HIV care at another program. As such, 
the composite attrition variable (death or LTP) constitutes a sub-optimal summary of the 
patient experience after leaving a program. However, we anticipate that a significant 
proportion of patients classified as LTP either died or completely disengaged from care; 
given that both these events compete for the identification of failure, we believe that 
structuring the analysis in this way allows for the most conservative estimates given the 
limitations of these data. In addition, this analysis may under estimate loss to program as 
children who has no follow-up time on ART were excluded from this analysis however as 
retention was not the focus of this analysis, this does not impact the key findings of this 
paper. As noted previously, failure was identified as the first episode of meeting clinical, 
immunologic, or viral criteria, and interventions other than a change to second-line therapy 
may have occurred (e.g., adherence counseling, referral to a support group, assignment of a 
peer navigator, etc.). Unfortunately, alternative interventions could not be assessed in this 
analysis. In addition, missing data on clinical events and laboratory testing such as CD4 cell 
counts and VLs may have led to an underestimate of the cumulative risk of failure over time.
Despite these significant limitations, the strengths of this analysis are that the data are from a 
large geographically diverse cohort that is representative of the HIV-infected pediatric 
population receiving ART in sub-Saharan Africa and Asia. In addition, this is one of the few 
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studies that has been able to assess the incidence of failure, based on the monitoring 
strategies utilized by the programs, and assess time from an indication of failure to transition 
to second-line ART.
In conclusion, based on this analysis, approximately a quarter of pediatric HIV patients in 
sub-Saharan Africa and Asia experience at least one failure event within five years of ART 
initiation. However, the rate of change to second-line ART regimens was low. Further 
studies are needed in order to understand how HIV programs healthcare providers assess and 
respond to treatment failure events.
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Figure 1. 
Cohort Composition
Wools-Kaloustian et al. Page 14
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
a. Cumulative Incidence of Failure and Death/Loss to program after ART-initiation
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b. Cumulative Incidence of Change to second-line and Death/Loss to Program after a Failure 
Event
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Table 1
Patient Demographics and Distribution by Site Characteristic
Characteristic N (%)
Region
  Asia-Pacific 1935 (7.2)
  Central Africa 1.0 49 (0.2)
  Central Africa 2.0 1550 (5.7)
  East Africa 7511 (27.8)
  Southern Africa 14270 (52.8)
  West Africa 1716 (6.4)
Affiliation
  Academic 2225 (8.2)
  Public 16055 (59.4)
  Non-profit 8239 (30.5)
  Missing 512 (1.9)
Location
  Urban 12413 (45.9)
  Rural 860 (3.2)
  In-between 13321 (49.3)
  Missing 437 (1.6)
Type
  Children only 18685 (69.1)
  Family Clinics 7088 (26.2)
  Missing 1258 (4.7)
Year Started Providing ART
  Prior to 2004 16993 (62.9)
  2004 and after 10038 (37.1)
Female 13339 (49.4)
Initial Regimen Type
  NNRTI-based 25512 (94.4)
  NRTI-based 80 (0.3)
  PI-based 1439 (5.3)
Median (IQR)
Age at first visit 6.1 (3.5–9.1)
Age at ART start 6.7 (4.2–9.7)
CD4 count at ART start (cells/µl)* 258 (112–444)^
CD4% at ART start‡ 13.2 (8.7–19.0)^
*
Patients >= 5 years old
^Closest within 90 days prior and 7 days post ART initiation
‡
Patients <5 years old
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